No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .
Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.
Despite the beneficial effects of blockade of the renin-angiotensin system in diabetic nephropathy ( DN ) , albuminuria and progression of renal disease are not completely halted by these agents . Therefore , it is necessary to explore potential antiproteinuric and renoprotective effects of innovative therapeutic approaches . This study tested the hypothesis that the combination of pentoxifylline ( PTF ) with angiotensin II receptor blockers in normotensive patients with type 2 diabetes produces an additive antiproteinuric effect .  Sixty-one patients with DN and residual albuminuria despite treatment with the recommended doses of ARB for > 1 yr were r and omly assigned to receive the addition of 1200 mg of PTF daily ( n = 30 ) or to a control group ( n = 31 ) . Baseline characteristics were similar between groups , and correlation analysis showed a significant association between urinary albumin excretion ( UAE ) and urinary TNF-alpha ( R = 0.53 , P < 0.001 ) . After 4 mo , albuminuria showed a significant decrease in patients who received PTF , from 900 mg/24 h ( 466 to 1542 mg/d ) to 791 mg/24 h ( 309 to 1400 mg/d ; P < 0.001 ) , whereas no significant changes were observed in the control group : 920 mg/24 h ( 450 to 1489 mg/d ) at baseline , and 900 mg/24 h ( 428 to 1800 mg/d ) at the end of the study . The mean percentage variation of UAE in the treatment and control groups was -16.7 and 5.5 % , respectively ( between-group comparison , P < 0.001 ) . This additive antiproteinuric effect was not dependent on changes in BP or metabolic control . However , both serum and urinary levels of TNF-alpha also decreased in patients who received PTF , from 6.4 pg/ml ( 2.1 to 9.7 ) and 16 pg/mg ( 8 to 29 ) at baseline to 4.6 pg/ml ( 0.4 to 9 ) and 14.2 pg/mg ( 3 to 26 ) at the end of the study , respectively ( P < 0.01 ) , without significant variations in control patients . Moreover , regression analysis at the end of the study showed a correlation between the change in UAE and the change in urinary TNF-alpha in patients who were treated with PTF ( R = 0.49 , P < 0.001 ) . In conclusion , administration of PTF to patients who have type 2 diabetes and are under long-term treatment with an ARB produces a significant additive antiproteinuric effect associated with a reduction of urinary TNF-alpha excretion
No alteration in plasma IL-6 concentration was observed .
Pentoxifylline did not alter BP or plasma IL-6 concentration , but significantly reduced circulating TNF-α and CRP concentrations
INTRODUCTION Pentoxifylline is a xanthine derivative with potential cardiovascular benefits .
AIM To evaluate the impact of pentoxifylline on  blood pressure ( BP )  and plasma TNF-α , C-reactive protein ( CRP ) and IL-6 through a systematic review and meta- analysis of r and omized controlled trials .